Key Takeaways
- Pharma outperforms, chemicals still loss-making: The non-ibuprofen API portfolio drove pharma growth while the chemicals division remained in the red, though management expects a return to profitability in Q4 as high-cost inventory and maintenance downtime clear.
- Regulatory approvals unlock regulated markets, but revenue lags: EU GMP certification, CEPs, and a Korean FDA approval were secured, yet stability testing and customer qualification mean commercial benefit is still a few quarters away.
- Ibuprofen pricing floor called: Management stated ibuprofen export pricing is stable at $11–$12 and does not anticipate it going down at all, even as domestic realizations sit lower.
- Portfolio de-risking underway on both sides: The company is adding products to the non-ibuprofen pharma portfolio and changing the chemical product mix, with more details promised at the next quarterly meeting.
- What to watch next quarter: Whether the chemical division actually returns to profitability, the pace of non-ibuprofen sales ramp-up now that capacity expansion is stabilized, and any early commercial traction from the newly obtained European regulatory approvals.
Pharma: The Growth Engine
- Non-ibuprofen is where the real growth lives: With ibuprofen asset utilization already above 80%, marginal volume gains add little; management explicitly stated the real growth will come from the non-ibuprofen portfolio.
- Q3 dip was capacity expansion, not demand: Non-ibuprofen API revenue fell QoQ because the company took downtime to expand capacity for one product and stabilize the process at higher scale. Most of the increase is now expected in Q4.
- Profitability turning soon: Unabsorbed costs from the expansion are declining every quarter, and management expects the entire non-ibuprofen segment to turn profitable in the coming quarters.
- Next-year ambition: Management expects non-ibuprofen sales to exceed ₹500 crores next year, though it declined to commit to a specific growth rate when pressed.
- Ibuprofen demand ticking up: Demand was substantially up versus Q2, with European markets back to pre-COVID levels and a further increase observed in the current quarter. Capacity utilization is expected to improve, though reaching 95% peak may take a few more quarters.
- Regulated-market toolkit assembled: CEP approvals, an EU GMP certificate from Hungary, Korean FDA approval, and a Russian authority approval were all received in the last 2–3 quarters. The front-end team is now engaging customers, but stability testing means commercial benefit lags by a few quarters, an industry-wide reality.
Chaturvedi: "The good news is that we've got the right tools to play with. We've got the right products. We've got the right approvals. We've got the right team who's talking to the right set of customers, and now it's a question of time before you start to see the commercial benefit of all this."
Chemicals: Bottoming Out
- Still loss-making, but Q4 turnaround promised: The chemical division posted an EBIT loss in Q3, though better than Q2. Slightly lower volumes and pricing, plus the consumption of high-cost inventory and a few extra days of maintenance downtime, drove the sequential decline. Management stated all of this is now behind and the business should return to profitability in Q4.
- Margins have bottomed: Raw material prices for certain specialty chemical products have stabilized, though some are yet to do so. Management believes the worst is over and margins have bottomed out for most product lines.
- Ethyl acetate spread improving: Acetic acid and ethyl acetate prices move in sync with a phase lag; the current spread gives management comfort that profitability will improve. Ethyl acetate volumes remain flat at high asset utilization.
- Product mix change coming: The company is not expanding ethyl acetate capacity; instead it is changing the product mix on the chemical side, with more details promised at the next quarterly meeting.
- Inventory is lean: Hardly any finished goods inventory is held; raw material inventory is carried for a few months.
Pricing & Input Costs
- Ibuprofen pricing called stable: Export pricing sits between $11 and $12, with domestic prices slightly lower. Management does not anticipate pricing going down at all.
- Pain management price surge is transient: A recent price spike in ibuprofen, paracetamol, and naproxen was described as a one-off with no fundamental underlying demand reason for a surge in demand or increase in prices; it will stabilize.
- Broad input cost pressure: Volumes have gone up to deliver performance, but input costs pressured margins. Ethyl acetate prices dropped over 30%, paracetamol approximately 30%, metformin 20–25%, while ibuprofen was flat to a modest decline.
- Energy and freight easing: Pricing on both logistics and energy fronts is easing, which will help boost margins going forward.
- DCDA volatility a managed risk: DCDA prices swung from $3,500–$3,600/ton to $2,200/ton over the last year; profitability in Metformin depends on having the right sourcing strategy and partners.
- Competitor pricing gap deflected: When an analyst noted IOL's average ibuprofen realization appears significantly lower than a competitor's based on export data, management questioned whether the gap was real and redirected the question to profitability rather than price, without directly explaining the apparent realization difference.
Chaturvedi: "I'm not sure that's necessarily true. And what I'd like you to do is take a look at not just the price realization, but the profit realization because I think the question to be asked is if my peers and competitors are selling at a higher price, why are they not more profitable?"
Regulatory & IP Milestones
- Patent grants stacking up: A patent was granted for an improved safe process for preparing Sartan drugs (Valsartan, Losartan, Irbesartan, Olmesartan, Candesartan, and others). A separate process patent on Sitagliptin was also received.
- Commercial value of patents: The Sartan patent enables offering products with lower impurity levels. The Sitagliptin patent delivers environmental and cost benefits by using less raw material.
- Sitagliptin still pre-commercial: The product is under pilot/development; the company has started working with customers but says it is too early to estimate market share or whether it will be sizable.
- Paracetamol capacity expanded: Capacity has been increased to 3,600 tons; the process is now stabilized and the plant will run at that capacity in coming months, with 90% utilization expected one year down the line.
Strategy & Capital Allocation
- Portfolio de-risking is the theme: Management intends to de-risk the entire portfolio by adding more products, and will do the same on the chemical side.
- Western India investment postponed: Given the current macroeconomic environment, the company is better off postponing the investment; enough investment has been made in the current facility to manage growth for at least the next year or so.
- CapEx run-rate: Typical annual CapEx is around ₹150 crores, split between pharma and chemicals.
- US investment still under study: The minority position in a US company with a technology platform is undergoing an in-depth study to figure out monetization; it will take time and is not expected to directly help sell more APIs into regulated markets.
- Backward integration focus: The company is working on developing backward integration models to reduce dependence on imported raw materials, a strategy management believes will pay off in the coming few quarters.
Chaturvedi: "I will say that a specialty chemicals and an API business is a lot like an iceberg. The financial numbers that you see don't quite articulate the holds of employees and other stakeholders that actually enable these numbers."
Industry Context & Margin Trajectory
- Equilibrium framework: Management's view is that at equilibrium, the API industry runs at an average EBITDA of 12% to 15%, with some companies delivering 20–25% and others closer to 8–10%.
- Business improvement is slow by nature: Improvement happens in years, not quarters; the impact of product portfolio improvements, capacity additions, and regulatory approvals is expected in the coming few quarters.
- Margin trajectory turning up: The company is almost at 10% EBITDA now and will be moving into double-digit territory. All indications, portfolio, customer feedback, and the order book suggest the worst is behind and things are improving.
- COVID-era comparison is misleading: Compared to four years ago, current performance is not underperformance; the COVID period saw overstocking and a surge, and some leading API players took massive profitability hits as COVID products went away.
Chaturvedi: "And in this industry, business improvement happens in years, not in quarters."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Chemical division profitability | Return to profitability after high-cost inventory and maintenance downtime clear | Q4 FY23 |
| Non-ibuprofen sales | Exceed ₹500 crores | This year (FY23) |
| Non-ibuprofen segment profitability | Entire segment turns profitable | "Next coming quarters" |
| Ibuprofen pricing | No decline anticipated from current $11–$12/kg export range | Ongoing |
| Ibuprofen capacity utilization | Reach 95% peak utilization | "Another few quarters" |
| Paracetamol capacity utilization | Reach 90% | One year down the line |
| Western India investment | Postponed given macro environment; current facility sufficient for growth | At least next year or so |
| Regulated market commercial benefit | Revenue from CEPs and EU GMP approvals | "A few more quarters" |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Total income | ₹530 cr, vs ₹564 cr YoY and ₹546 cr QoQ |
| EBITDA | ₹49.7 cr, vs ₹68.1 cr YoY and ₹36.7 cr QoQ |
| EBITDA margin | 9.4%, vs 6.8% QoQ |
| Net profit | ₹24 cr, vs ₹40 cr YoY and ₹15.7 cr QoQ |
| Exports (9M FY23) | ₹431 cr, grew 26% YoY from ₹368 cr |
| Net cash | ~₹300 cr as of December 2022 |
| Ibuprofen export pricing | $11–$12/kg, stable; India prices slightly lower |
| Ibuprofen capacity utilization | North of 80%, expected to improve further |
| Non-Ibuprofen API revenue (FY23E) | ~₹500 cr, delivered in 9M what it did in full FY22 |
| Chemical capacity utilization | Well above 95% |
| Ethyl acetate pricing | ₹83–₹84/kg, not completely flat; slightly lower QoQ |
| Acetic acid pricing | ~₹40/kg, stable |
| Paracetamol capacity | 3,600 tons, process stabilized; domestic price ₹530–₹550/kg |
| Paracetamol expected utilization (1 year) | 90% |
| CapEx spent (FY23) | ~₹150 cr, typical annual run-rate |
| Revenue from exports (overall) | ~27% of total revenue |